MSD - MRK Net earnings per share (EPS TTM)

Official company branding of Merck (MRK)

The global manufacturing network of Merck & Co., Inc. (MRK) ensures a stable drug output, which is corroborated by the EPS trend over the last 12 months. Robert Davis's strategic deals support the capitalization despite regulatory pressure and the risk of Keytruda patent expirations. Meanwhile, the value of 0.99 reflects the metric's balance, linking the business's real yield with management's long-term goals and actual earnings per share.

MRK (Merck & Co., Inc.) Net earnings per share for the last four quarters history from 07/04/2022 to 11/12/2026

Analytical breakdowns for Merck & Co., Inc.

- current quotes and average value forecast:
Price Chart Merck & Co., Inc.|MRK - Price Target Chart
- issuer market value details:
Market Capitalization Merck & Co.|MRK - Business Value
- business book valuation details:
Book Value per Share Merck|MRK - Book Valuation of Business|Market Value to Book Value Ratio merck.com|MRK - Total Business Assets
- debt burden and liquidity indicators:
Total Debt to Capital Merck & Co., Inc.|MRK - Long-Term Indebtedness to Equity|Short-Term Debt to Equity Merck Sharp & Dohme|MRK - Company Total Debt|Debts to Book Capitalization Merck & Co.|MRK - Long-Term Debt|Company Short-Term Debt Merck|Quick Ratio merck.com
- net income and valuation multiples indicators:
MRK - Net Income|Expected Profit Merck & Co., Inc.|MRK - P/E Multiple|Projected Price to Earnings Merck|MRK - Growth-Adjusted Payback Ratio|Enterprise Value to Operating Income Before Depreciation Merck & Co.|MRK - Company profit before taxes, interest and amortization|Net earnings per share for the last 12 months Merck|MRK - Earnings per share for the trailing year|Quarterly EPS earnings growth merck.com|MRK - Net earnings per share growth this year|Net earnings per share growth forecast for next year Merck & Co., Inc.
Initial company analysis:Merck & Co., Inc. (MRK)
Manufactured products of Merck Sharp & Dohme

This metric reflects the actual equity value of earnings, calculated as the ratio of net income to the number of shares outstanding over the past year. Analyzing the trailing 12-month net income per share allows for the removal of volatility and an assessment of Rob Davis's strategy to diversify the drug portfolio to neutralize patent risks for Merck & Co., Inc. (MRK).

Main competitors

LLY - Earnings per share for the last twelve months|ABBV: Earnings per share for the last twelve months|AZN: Net earnings per share (EPS TTM)|Earnings per share for the last 12 months NVS|NVO (Novo Nordisk Inc.) - Net earnings per share (EPS TTM)|Amgen Inc (AMGN) - Net earnings per share for the last four quarters|Earnings per share for the last twelve months Pfizer Inc. (PFE)|sanofi.com - Earnings per share for the last 12 months|Net earnings per share (EPS TTM) BMY (Bristol Myers Squibb)|Net earnings per share for the trailing year GlaxoSmithKline plc|TAK - Earnings per share for the last twelve months|Teva Pharmaceutical Industries (TEVA) - Net earnings per share for the last 12 months|RDY: Net earnings per share (EPS TTM)|Net earnings per one share for the last twelve months viatris.com (VTRS)|Earnings per share for the last twelve months Roivant Sciences|ZLAB: Earnings per share for the trailing year|Net earnings per share (EPS TTM) BHC|Net earnings per share for the last 12 months Cosmos Health Inc COSM